semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Cervical Intraepithelial Neoplasia Histological evidence of CIN I and II 2. Transformation zone and lesion margins fully visible 3. Compliant subject 4. Safe contraception 5. Negative pregnancy test  Lesion related 1. CIN III, (micro)-Invasive Cancer 2. Endocervical lesion, upper margin of lesion not visible on colposcopy 3. Non-compliance of patient 4. PAP V Drug related 1. Age > 60 2. Hypersensitivity to progesterone or any component of the formulation 3. Thrombophlebitis 4. Undiagnosed vaginal bleeding 5. Carcinoma of the breast 6. Cerebral apoplexy 7. Severe liver dysfunction 8. Pregnancy 9. Depression 10. Diabetes 11. Epilepsy 12. Migraine 13. Renal dysfunction 14. Asthma 15. HIV infection 16. Hepatitis B or C 17. Concurrent use of anticoagulants 18. Uncontrolled hypertension (> 160/90 mmHg) 19. Breast cancer in personal history 20. Concurrent hormonal therapy including OC Clinical laboratory related 1. Hemoglobin < 11 g/dl 2. Leukocytes < 4,0 x 109/L 3. Platelet count < 100 x 109/L 4. Serum bilirubin > 2 x above upper cut-off value 5. Serum GOT > 2 x above upper cut-off value 6. Serum GPT > 2 x above upper cut-off value 7. Serum alkaline phosphatase > 2 x above upper cut-off value 8. Serum creatinine > 2 x above cut-off value
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervix Cancer Patients with abnormal Pap smears who are referred for colposcopy  Anyone of the male sex since this study focuses on cervical cell abnormalities Any woman who has had a hysterectomy, LEEP, or chemotherapy
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-30.0,  Healthy Female through 30 years of age (must not have reached the 31st birthday) Unless previously surgically sterilized, agrees to use an effective method of birth control (e.g., abstinence, intrauterine contraceptive device, oral contraceptives, diaphragm or condom in combination with contraceptive jelly, cream or foam, Norplant® or DepoProvera®) beginning 30 days before the first study injection and continuing through 60 days after the final study injection Healthy by medical history and physical examination Cervical specimen positive for HPV-16 and/or HPV-18 DNA using the Digene Hybrid Capture® II HPV test within 21 days of study entry Cervical cytology by Pap smear that is either normal or no greater than ASCUS or AGCUS, using the Cytyc ThinPrep® Pap Test, within 21 days of study entry (a normal Pap smear must also be adequate for interpretation; a Pap smear that is normal but inadequate for interpretation must be repeated). Those volunteers with ASCUS or AGCUS must have had a clinical evaluation by colposcopy within the previous month which showed no evidence of CIN or SIL No evidence of anogenital HPV lesions or no physical findings suggestive of other gynecologic pathogens on pelvic examination within 21 days of study entry Agrees to no other experimental therapy or vaccines until 30 days after the last study injection Written informed consent obtained from the volunteer  Acute illness or fever (oral temperature ³99.5°F [37.5°C]) at start of the study History or clinical manifestations of significant medical or psychiatric disorder Pregnant or lactating Use of immunosuppressive medication (inhaled and topical corticosteroids are permitted) within the previous 90 days or history of immunodeficiency History of cancer History of alcohol or drug abuse within the past 2 years At screening (must be within 21 days of study entry) any of the following: hemoglobin <11 gm/dL; white blood cell count <4000/mm3; platelet count <120,000/mm3; AST, ALT, creatinine >1.5x upper limit of normal for the laboratory in question; other abnormal laboratory values in the screening panel which in the opinion of the principal investigator are judged to be clinically significant Receipt of immunoglobulin or blood products within 90 days prior to study entry History of Pap smear more severe than ASCUS or AGCUS Positive tests for hepatitis C antibody, hepatitis B surface antigen, or HIV-1 antibody
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Papilloma Virus, Human Abnormal pap smear ASCUS or higher Age 18-postmenopausal  Less than 18 years old Prior hysterectomy Pregnancy Use of corticosteroids HIV positive
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Histologically confirmed adenocarcinoma of the breast Clinical manifestations of metastatic disease If patient's tumor is HER2 positive (3+ by immunohistochemistry [IHC] or amplified by fluorescent in situ hybridization [FISH]), must have received at least one prior trastuzumab (Herceptin)-containing regimen unless there is a contraindication Measurable disease defined as at least one lesion whose longest diameter can be accurately measured The only evidence of metastasis must not be bone metastases or other non-measurable disease Nonmeasurable disease is defined as all other lesions, including small lesions (longest diameter < 2 cm) and truly nonmeasurable lesions which any of the following Bone lesions Leptomeningeal disease Ascites Pleural/pericardial effusion
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 19.0-65.0,  Cervical Cancer Women who have a diagnosis of cervical cancer 2. Women who are scheduled for either a radical hysterectomy or radical trachelectomy at the British Columbia Cancer Agency Vancouver Cancer Centre 3. Proficient in English  No woman who meets the will be excluded from participating
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 26.0-999.0,  Infections, Papillomavirus Papillomavirus Vaccines A woman who the investigator believes that she can and will comply with the requirements of the protocol A women of at least 26 years of age at the time of the first vaccination Written informed consent obtained from the subject prior to enrolment Free of obvious health problems as established by medical history and clinical examination before entering into the study Subject must have intact cervix Subject must have a negative urine pregnancy test. This test is not applicable to women of non-childbearing potential Subject must be of non-childbearing potential or, if of childbearing potential, she must be abstinent or must be using an effective method of birth control for 30 days prior to the first vaccination and must agree to continue such precautions for two months after completion of the vaccination series  Pregnant or breastfeeding (women must be at least three months post-pregnancy and not breastfeeding to enter the study) A women planning to become pregnant, likely to become pregnant (as determined by the investigator) or planning to discontinue contraceptive precautions during the vaccination phase of the study, i.e. up to two months after the last vaccine dose (Month 0 Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period (up to Month 84) Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after (i.e. days 0 the first dose of study vaccine. Planned administration/administration of routine vaccines up to 8 days before the first dose of study vaccine is allowed. Enrolment will be deferred until the subject is outside of specified window Previous administration of components of the investigational vaccine Previous vaccination against HPV or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period History of HPV infection/treatment or planned treatment to evaluate an abnormal cervical cytology (Pap smear) test, e.g. colposcopy Any medically diagnosed or suspected immunodeficient condition based on medical history and physical examination
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Papillomavirus Infections A female subject of childbearing potential who is sexually active using contraception Subject is willing to abstain from all sexual contact involving her genitalia for at least 24 hours prior to and 24 hours after study drug administration Subject must be neither pregnant nor lactating from Screening throughout the duration of the study Subject has 1 of the following Menstruating with a stable cycle and has at least 21 non-bleeding days Amenorrheic (due to injectable or extended-cycle contraceptives) Subject is willing to refrain from using vaginal douche products during the treatment period and through the Follow-up Month 4 visit Subject has a Pap test interpretation of either low-grade squamous intraepithelial lesions or atypical squamous cells of undetermined significance Subject has a uterine cervical sample that is high-risk human papillomavirus positive  The Subject has evidence of an uncontrolled, clinically significant medical condition as determined by the investigator The Subject has a history of hemorrhagic diatheses or coagulopathy The Subject has a history of toxic shock syndrome The Subject has received any of the following medications in the timeframes listed below (in any form) or an active (non-placebo) human papillomavirus vaccine at any time prior to the screening visit In the 4 weeks prior to the screening visit the subject has received Interferon therapy or other therapies that promote a proinflammatory immune state, including immunomodulators cytotoxic drugs drugs known to have major organ toxicity
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-120.0,  Cervical Cancer Cervical Intraepithelial Neoplasia CIN All women who are referred for cervical colposcopy to the University of Oklahoma will be considered eligible for the study. These women will be categorized into four groups: (i) cancer, (ii) precancer, (iii) HPV-infected, and (iv) normal. Cancers will be limited to women diagnosed with early cancer (Stage 1-2) to minimize potential disease effects. Precancers will be defined as women diagnosed histologically with cervical intraepithelial neoplasia 3 (CIN3). This is a highly specific and well-reproduced diagnosis which effectively represents carcinoma in situ. All women testing DNA positive for any of the 13 known oncogenic HPV types (HPV-infected), but not diagnosed with CIN3 or cancer (all stages) will be placed in the HPV-positive group. This group will therefore encompass all HPV-infected women diagnosed with either cervical intraepithelial neoplasia 1 (CIN1), CIN2, low grade squamous intraepithelial lesion (LSIL), atypical squamous cells of undetermined significance (ASCUS), atypical glandular cells of underdetermined significance (AGUS), or found cytologically normal. Women referred to the colposcopy clinic but found to be negative for oncogenic HPV and normal upon histological diagnoses will be eligible as normal controls; this approach will be an ethical method for collecting biopsies from essentially "normal" women as there are many benign "look alike" conditions that are ruled out in colposcopy clinics. While this group may not be a random sample of the general population, the use of specimens from these women as controls will ensure a group of women who are truly confirmed as having no neoplasia  Women attending the clinic solely for vaginal colposcopies will be excluded from the study. Women who are under 18 years of age or pregnant at the visit will also be excluded from the study. In addition, women who have had prior treatment (women coming to the clinic for a follow-up visit subsequent to treatment (women coming to the clinic for a follow-up visit subsequent to treatment or women coming for their initial clinic visit following pretreatment with chemotherapy or radiation) will be excluded. All women with known HIV or AIDS will be excluded from the study. This information will not be readily available unless the woman has previously been seen at the University of Oklahoma clinic. This event is considered rare; recent studies of HIV and AIDS by the University of Oklahoma from the same population have been terminated due to the lack of HIV/AIDS detected in the population
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-75.0,  Cervical Cancer Patients undertaken radical hysterectomy with diagnosis of invasive cervical cancer Ib-IIa (non-small cell type) Patients must have at least one of the following risk factors; pelvic lymph node involvemet, involvement of vaginal resection margin,parametrial invasion Patients must have a GOG performance of 0, 1, or 2 Patients must have expected life span over 6 months  Patients with peripheral neurotoxicity over grade 2 in CTC criteria Patients with history of chemotherapy or radiation treatment Patients with histologicallly proven or highly suspected metastasis to paraaortic lymph node Patients with history of hypersensitive reaction to platinum agent
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Cervical Neoplasia FOR PHASE OF STUDY: Less than 35 years of age. Intact uterus (non-hysterectomized). In good general health. Non-pregnant. For women not using OCs: Having regular cycles [cycles 25-35 days in length]. HPV16 seropositive [based on data from latest visit tested]. No evidence of HSIL/cancer [based on data from latest visit within cohort]. Willing to participate [informed consent]. FOR PHASE OF STUDY: Must be between the ages of 45 to 70 years. Women who do not have a final diagnosis of HSIL
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  HPV Women age 21 and older Non-pregnant, non-hysterectomized  Pregnant women and women under the age of 21 will not be included in this study
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Prostate Cancer Colorectal Cancer Breast Cancer Cervical Cancer Lung Cancer Enrolled in Medicare Part B Self-reported American Indian  Have cancer other than study cancer Medicare Part C enrolled
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Malignant Breast Cancer, Benign Breast Lesions Women carrying benign breast lesions will be further divided and analyzed according to the Fitzgibbon's risk categories for invasive cancer risk (4). The Fitzgibbon's categories are: 1. No increased risk group including adenosis (other than sclerotic), duct ectasia fibroadenoma without complex features, 2. slightly increased risk group (1.5-20 times) which includes fibroadenoma with complex features, moderate or florid hyperplasia without atypia, sclerosing adenosis, 3. moderately increased risk group (4.0-5.0 times) includes atypical ductal and lobular hyperplasia and 4. markedly increased risk group (8.0-10.0 times) which includes ductal and lobular carcinomas In Situ Following the blood collection, detailed relevant clinical information of the patient will be registered in a case record form. The data will age, country of birth, last menstrual period, lactation, number of children, age at first full-term pregnancy, age at onset of menopause, family history, medication, mammography findings, FNA results, tumor size, histological findings, biopsies, disease staging, and other relevant clinical information  pregnancy, 2. experiencing menstruation, or 3. under hormonal or drug treatment
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Uterine Cervical Cancer Age between 18 and 70 years old Cervical uterine cancer (epidermoid or adenocarcinoma, stage:from IB> or = 4 cm to IV, according to FIGO classification) histologically proven Measurable lesions,clinically and by MRI assessed PS-WHO < or = 2 ou Karnofsky Index >70 per cent Life expectancy > 3 months Hematologic function: leukocytes < or = 3 G/l, polynuclear neutrophil leukocytes > or = 1.5 G/l, platelets > or = 100 G/l, hemoglobin > or = 10 g/dl Hepatic function: ASAT and ALAT < 2.5 ULN Renal function: creatininemia < 1.5 ULN, clearance > 60 ml/min No prior chemotherapy or radiotherapy Contraception  Stage IB < 4 cm or IVB Other histology than epidermoid or adenocarcinoma Distant metastases, including sus-clavicular adenopathy Contraindication to MRI Pregnant or lactating woman Auto-immune disease Peripheric neuropathy, autograft or homograft, psychiatric disease Prior cancer (except cutaneous basocellular carcinoma and uterine cervical carcinoma in situ) Active infection Other clinical trial with an experimental drug
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 21.0-100.0,  Cervical Neoplasia Women in KPNC aged 25 years or older who tested positive for HPV. Will also a random sample of women who tested negative for HPV  Male. Children under 18
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hematological Malignancies Histologically or cytologically confirmation of AML, MDS, CML in blast phase, myelofibrosis, CLL, or aplastic anemia There are no limitations on additional, allowable type and amount of prior therapy as long as acute toxicities have resolved to the allowable grade Must have normal organ functions Must be willing to submit to blood sampling for the planned PK and PD analyses Must have the ability to understand and willingness to sign a written informed consent form  No other agents or therapies administered for the intent to treat Uncontrolled, intercurrent illness Pregnant women and women who are breast feeding